Hormone therapy, more precisely called endocrine therapy, is one of the most important and effective treatments available for breast cancer. It is recommended for women and men whose breast cancer is driven by the hormones oestrogen and/or progesterone, and it works by either reducing the amount of oestrogen in the body or blocking oestrogen from reaching and stimulating cancer cells.

Hormone receptor-positive (HR-positive) breast cancer accounts for approximately 70 to 75% of all breast cancers. These tumours express receptors on the surface of their cells that bind to oestrogen, which acts as a growth signal. By cutting off or blocking this signal, endocrine therapy can prevent cancer cells from being stimulated to grow and divide, both reducing the risk of recurrence and, in advanced disease, slowing tumour growth.

Endocrine therapy is taken as a daily tablet, typically for a minimum of five years and often for ten years or more following primary breast cancer treatment. It is not chemotherapy, it does not cause hair loss or severe nausea, and for the majority of patients it is manageable as part of everyday life. Understanding what it is, how it works, and what side effects to expect and how to manage them makes a significant difference to how patients experience this long-term treatment.

It is important to note that endocrine therapies used to treat breast cancer are quite different from hormone replacement therapy (HRT) used to manage menopausal symptoms. They have opposite mechanisms of action: endocrine therapy reduces or blocks oestrogen activity, while HRT supplements it.

Who Is Endocrine Therapy Recommended For?

Your oncologist will recommend endocrine therapy if your breast cancer is oestrogen receptor-positive (ER-positive) and/or progesterone receptor-positive (PR-positive), as determined by your core biopsy pathology report. This applies regardless of the stage of disease, from early-stage DCIS through to metastatic breast cancer.

For patients with early-stage, hormone receptor-positive breast cancer, endocrine therapy in the adjuvant setting (given after surgery) reduces the risk of the cancer recurring in the breast, in the lymph nodes, and at distant sites, and reduces the risk of developing a new primary breast cancer in the opposite breast. Its benefit is sustained and builds over years of treatment, which is why the duration of therapy has been progressively extended as evidence has emerged.

The specific endocrine therapy recommended depends primarily on your menopausal status, as this determines how much oestrogen your body produces and from which sources.

Types of Endocrine Therapy

Tamoxifen

Tamoxifen is a selective oestrogen receptor modulator (SERM). It works by attaching to oestrogen receptors on breast cancer cells and blocking oestrogen from binding to them, preventing the growth signal from reaching the cell. Tamoxifen can be used in women of any age, whether premenopausal or postmenopausal, and it is the standard endocrine therapy for premenopausal women.

Tamoxifen is taken as a single tablet daily. The standard duration is five years, though evidence from major clinical trials has established that ten years of tamoxifen provides additional benefit for women who remain premenopausal after five years, further reducing recurrence risk.

Common side effects include hot flushes, night sweats, vaginal dryness, changes in mood, and irregular periods. These are menopausal-type symptoms caused by the anti-oestrogenic effects of the drug and vary significantly between individuals. Many women experience no or minimal side effects; others find them more challenging. Importantly, these symptoms generally improve after treatment ends.

Less common but more serious potential side effects include an increased risk of blood clots (deep vein thrombosis and pulmonary embolism), stroke, and a small increase in the risk of uterine (endometrial) cancer. The absolute risk of these serious side effects is low and is substantially outweighed by the benefits of tamoxifen for women with hormone receptor-positive breast cancer. If you experience unusual leg pain or swelling, breathlessness, or any abnormal vaginal bleeding while taking tamoxifen, you should seek medical attention promptly.

Women taking tamoxifen who have not yet had a hysterectomy should have regular gynaecological review.

Aromatase Inhibitors

Aromatase inhibitors (AIs) work by blocking the enzyme aromatase, which is responsible for converting androgens (male hormones) into oestrogen in the body's peripheral tissues, including fat cells. This is the primary source of oestrogen in postmenopausal women, whose ovaries no longer produce significant amounts. By blocking aromatase, AIs dramatically reduce circulating oestrogen levels.

Because aromatase inhibitors work by suppressing peripheral oestrogen production (rather than blocking its action at the receptor, as tamoxifen does), they are only effective in postmenopausal women. In premenopausal women, the ovaries would simply compensate by producing more oestrogen in response to the reduced peripheral levels. The three aromatase inhibitors in common use are anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin).

Aromatase inhibitors are generally considered more effective than tamoxifen for postmenopausal women with hormone receptor-positive breast cancer, particularly for higher-risk disease, and are the preferred endocrine therapy in this group.

Common side effects include joint and muscle pain and stiffness (arthralgia), which affects a significant proportion of patients and can range from mild to quite limiting, as well as hot flushes, vaginal dryness, reduced libido, and fatigue. The arthralgia side effect is one of the most common reasons patients find it difficult to continue aromatase inhibitors. It is important to know that switching to a different AI or to tamoxifen is often possible if one agent's side effects are poorly tolerated.

The most clinically important long-term risk of aromatase inhibitors is bone loss (osteoporosis). By reducing oestrogen levels, AIs accelerate bone mineral density loss, increasing the risk of osteoporotic fractures. Patients taking aromatase inhibitors should have their bone mineral density (BMD) measured by DEXA scan at the start of treatment and periodically thereafter. Adequate calcium and vitamin D intake is recommended for all patients on AIs, and bisphosphonate or denosumab therapy may be recommended for women with significant bone loss or elevated fracture risk.

Ovarian Suppression

In premenopausal women, the ovaries are the primary source of oestrogen. Ovarian suppression reduces oestrogen to postmenopausal levels by preventing the ovaries from functioning.

Temporary suppression using GnRH agonists such as goserelin (Zoladex) or leuprolide, given as monthly or three-monthly injections, suppresses ovarian oestrogen production for as long as the injections are continued. Ovarian function generally returns after the injections are stopped.

Evidence from major clinical trials (SOFT and TEXT) has established that for premenopausal women with higher-risk, hormone receptor-positive breast cancer, combining ovarian suppression with either tamoxifen or an aromatase inhibitor provides superior recurrence reduction compared to tamoxifen alone. For women at intermediate or high risk of recurrence who are premenopausal, the combination of ovarian suppression with an aromatase inhibitor is now an important evidence-based option, though it carries a greater burden of menopausal symptoms than tamoxifen alone.

Permanent suppression can be achieved by surgical removal of the ovaries (oophorectomy) or, less commonly, by radiotherapy to the ovaries. These approaches cause a permanent surgical menopause and should be considered carefully, as they have implications for fertility, bone health, and cardiovascular health. Surgical oophorectomy may be particularly relevant for women who carry a BRCA1 or BRCA2 mutation, where it also substantially reduces ovarian cancer risk.

Duration of Endocrine Therapy

Endocrine therapy for early breast cancer is typically recommended for a minimum of five years. Evidence from clinical trials has established that extending treatment beyond five years provides ongoing reduction in recurrence risk for many women, and ten years of therapy is now commonly recommended for women at higher risk of late recurrence.

The decision about duration is made by your oncologist based on your recurrence risk, how you are tolerating treatment, and your personal circumstances. Extended treatment offers greater protection against late recurrence, which is a well-recognised feature of hormone receptor-positive breast cancer. The cancer can recur many years or even decades after the initial diagnosis if oestrogen continues to provide a growth stimulus, which is why long-term endocrine therapy is so important.

CDK4/6 Inhibitors: Enhancing Endocrine Therapy for High-Risk Disease

For women with high-risk early-stage, hormone receptor-positive, HER2-negative breast cancer, a class of drugs called CDK4/6 inhibitors has emerged as an important addition to standard endocrine therapy. These agents include abemaciclib (Verzenio) and ribociclib (Kisqali), which work by blocking proteins (CDK4 and CDK6) that cancer cells rely on to progress through the cell cycle and divide.

Clinical trials including MonarchE (abemaciclib) and MONALEESA trials (ribociclib) have demonstrated that adding a CDK4/6 inhibitor to adjuvant endocrine therapy significantly reduces the risk of recurrence in high-risk patients. Abemaciclib is taken twice daily as a tablet for two years alongside endocrine therapy. Your medical oncologist will assess whether CDK4/6 inhibitor therapy is appropriate for your risk profile.

Managing Side Effects of Endocrine Therapy

Side effects are the most common reason patients consider stopping endocrine therapy early, which is deeply counterproductive given the significant and sustained benefit of completing a full course. It is important to know that there are many strategies to manage side effects effectively, and that changing to a different endocrine agent is often possible if one is poorly tolerated.

Hot flushes and night sweats are among the most commonly reported side effects. Non-hormonal options for managing them include low-dose antidepressants such as venlafaxine, gabapentin, and clonidine, as well as lifestyle measures such as dressing in layers, reducing caffeine and alcohol, and using a fan at night. Some patients find that acupuncture helps. Topical oestrogen for vaginal symptoms is considered safe for many patients and should be discussed with your oncologist.

Joint and muscle pain (arthralgia) is particularly common with aromatase inhibitors. Regular exercise, including weight-bearing activity and strength training, has been shown to reduce arthralgia and is strongly recommended. Omega-3 fatty acid supplementation may provide modest benefit. If symptoms are significantly limiting, switching to a different AI or to tamoxifen is worth discussing with your oncologist.

Vaginal dryness and sexual health concerns affect many women on endocrine therapy. Vaginal moisturisers (used regularly) and lubricants (used during sex) are safe and effective first-line options. Topical vaginal oestrogen is generally considered safe for use in women with hormone receptor-positive breast cancer when symptoms are severe, though this should be discussed with your oncologist. Referral to a menopause specialist or sexual health clinician can be very helpful for women who are struggling with the impact of these symptoms on intimacy and relationships.

Bone health should be proactively monitored for women on aromatase inhibitors. Ensure adequate calcium (around 1200 mg daily from food and supplements combined) and vitamin D (consult your doctor for the appropriate dose), engage in regular weight-bearing and resistance exercise, avoid smoking, and limit alcohol. Your oncologist or GP will arrange DEXA scans to monitor bone mineral density and may recommend medication to protect bone health if needed.

Mood changes, fatigue, and cognitive effects are reported by some patients. Regular physical activity is one of the most effective evidence-based interventions for all three. Psychological support, sleep hygiene, and where necessary, referral to a psychologist or psychiatrist are all appropriate options.

The Critical Importance of Adherence

Endocrine therapy only works if it is taken consistently and for the full recommended duration. Adherence to long-term daily tablet treatment is a genuine clinical challenge, and studies consistently show that a significant proportion of patients reduce their dose or stop treatment early, often without informing their oncologist.

This matters enormously. The recurrence risk reduction from endocrine therapy is cumulative and builds over years of treatment. Stopping early, even after several years, meaningfully reduces the protection it provides. If you are struggling with side effects, please discuss this with your oncologist before stopping. In most cases, adjustments can be made, a different agent trialled, or supportive strategies introduced that allow treatment to continue.

If cost is a barrier (as some endocrine therapies are expensive, particularly CDK4/6 inhibitors), your oncologist or breast care nurse can advise on PBS access, pharmaceutical assistance programs, and other support options.

Endocrine Therapy for Advanced (Metastatic) Breast Cancer

In advanced or metastatic hormone receptor-positive breast cancer, endocrine therapy remains a cornerstone of treatment even though the disease is no longer curable. The goal in the metastatic setting shifts to controlling disease, relieving symptoms, and maintaining quality of life for as long as possible.

Endocrine therapy in combination with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) is the standard first-line treatment for most patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have not received prior chemotherapy. This combination substantially delays progression compared to endocrine therapy alone. Other targeted agents including everolimus (mTOR inhibitor) and alpelisib (PI3K inhibitor) are used in later lines of treatment when endocrine resistance develops.

Progestins such as megestrol acetate are occasionally used in later lines of treatment for metastatic hormone receptor-positive breast cancer and are generally reserved for situations where other options have been exhausted.

Endocrine Therapy at Breast & Surgical Oncology at The Poche Centre

Our surgeons work alongside specialist medical oncologists who prescribe and manage endocrine therapy for our patients. We remain involved in your care throughout the years of endocrine treatment, and we understand the challenges of long-term daily therapy. If you have concerns about side effects, adherence, or your endocrine treatment plan at any point, please speak with your breast care nurse, your oncologist, or our team.